#United States #healthcare #datma #Beaverton #Real-World Data

datma Reaches Major Milestone in Federated Real-World Data

In an exciting advancement for healthcare research, datma, a leader in providing federated access to real-world data, announced on March 12, 2025, that its innovative marketplace has hit a significant milestone: surpassing one million patient records available for research. This achievement underscores the strength of the datma.FED platform, which focuses on secure access to high-quality, multi-omic, demographic, electronic health records (EHR), genomic, and pathology data.

Launched in October 2024, the datma.FED platform allows pharmaceutical and research organizations to securely obtain valuable longitudinal genomic and pathology insights without the limitations of traditional data-sharing models. Traditional data repositories often necessitate data transfers to centralized locations, which can raise concerns regarding security and privacy. However, datma's federated approach enables researchers to perform secure queries without compromising data ownership, thus ensuring that organizations maintain full control over their data.

Noah Nasser, CEO of datma, highlighted the importance of this milestone, stating, "This expansion significantly enhances the depth and quality of genomic data accessible through the datma.FED platform. With over one million patient lives now represented, it becomes possible for researchers and pharmaceutical companies to gain deeper insights into genomic testing patterns while ensuring the highest standards of privacy and data stewardship. By connecting the appropriate data with the appropriate researchers, we are accelerating discovery while mitigating the challenges traditionally associated with data-sharing."

The integration of specialized molecular profiling with comprehensive genomic datasets fills a crucial void that has been present in pharma's existing real-world datasets. While existing data from claims and EHRs can offer insights into diagnoses or treatments, they often fall short in terms of providing detailed information about molecular testing. By including genomic and pathology data, pharmaceutical companies can now gauge biomarker prevalence, analyze molecular testing trends, and identify gaps in testing uptake—all of which are critical for refining market access strategies.

One of the standout features of datma.FED is its regulatory compliance. The platform adheres to HIPAA regulations, thus ensuring that sensitive patient information is adequately protected. Moreover, datma.FED eliminates the laborious process of manual data preparation and integration by standardizing and harmonizing healthcare data. This process enables research-ready data to be immediately accessible for inquiries by pharmaceutical and research teams.

As datma continues to broaden its data network, it remains committed to bridging the gap between real-world data and its practical applications in research and precision medicine. The innovations offered by datma represent a transformative shift in how healthcare data can be utilized—not just for analysis but also for fostering innovation, enhancing patient outcomes, and ultimately reshaping how healthcare organizations leverage their data assets.

About datma

Founded and headquartered in Oregon, datma is at the forefront of revolutionizing the landscape of healthcare data sharing. Their mission is to empower healthcare organizations through the optimization of data assets and the promotion of advanced data storage, AI-driven data harmonization, and federated query technologies. By creating secure collaborative environments between data custodians and researchers, datma successfully facilitates the analysis of rich, decentralized datasets without jeopardizing privacy. This not only allows health systems to generate secondary revenue through innovative data-sharing models but also enriches clinical practices and research throughput.

For more details, visit www.datma.com.